/CTXR
CTXR Stock - Citius Pharmaceuticals, Inc.
Healthcare|BiotechnologyNASDAQ
$1.07+4.39%
+$0.04 (+4.39%) • Dec 19
51
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.19
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.60
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $1.18
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for CTXR
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$1.06 – $1.08
TARGET (TP)$1.23
STOP LOSS$0.98
RISK/REWARD1:1.8
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.51
52W High$5.95
52W Low$0.65
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | $-209,611 | $-194,316 | $-179,677 | $-164,868 | $-152,364 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-41,995,681 | $-36,732,018 | $-33,316,045 | $-23,531,894 | $-17,710,685 |
| Net Income | $-39,138,839 | $-32,542,912 | $-33,640,646 | $-23,125,190 | $-17,548,085 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-5.97 | $-5.57 | $-5.76 | $-5.64 | $-0.45 |
Company Overview
Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of critical care products focusing on anti-infective products in adjunct cancer care, prescription products, and mesenchymal stem cell therapy. The company is developing five proprietary products comprising Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome; and I/ONTAK, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
1
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
1 Bullish0 Neutral/Bearish
Price Targets
$9
Average Target
↑ 741.1% Upside
Now
$9
Low
$9
Average
$9
High
Based on 1 analyst
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 30th 2024 | D. Boral Capital | Upgrade | Buy | $9 |
Earnings History & Surprises
CTXRBeat Rate
18%
Last 17 quarters
Avg Surprise
-294.8%
EPS vs Estimate
Beats / Misses
3/10
4 met exactly
Latest EPS
$-0.80
Q3 2025
EPS Surprise History
Q4 23
-300.0%
$-1.75vs$-0.44
Q1 24
-146.2%
$-1.50vs$3.25
Q2 24
+16.7%
$-1.25vs$-1.50
Q3 24
-20.0%
$-1.50vs$-1.25
Q1 25
-4275.0%
$-1.75vs$-0.04
Q1 25
-4.0%
$-1.30vs$-1.25
Q2 25
-17.6%
$-1.27vs$-1.08
Q3 25
-233.3%
$-0.80vs$-0.24
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 12, 2026 | — | — | — | — |
Q4 2025 | Dec 26, 2025 | $-0.24 | — | — | — |
Q3 2025 | Aug 12, 2025 | $-0.24 | $-0.80 | -233.3% | ✗ MISS |
Q2 2025 | May 14, 2025 | $-1.08 | $-1.27 | -17.6% | ✗ MISS |
Q1 2025 | Feb 14, 2025 | $-1.25 | $-1.30 | -4.0% | ✗ MISS |
Q1 2025 | Jan 3, 2025 | $-0.04 | $-1.75 | -4275.0% | ✗ MISS |
Q3 2024 | Aug 12, 2024 | $-1.25 | $-1.50 | -20.0% | ✗ MISS |
Q2 2024 | May 14, 2024 | $-1.50 | $-1.25 | +16.7% | ✓ BEAT |
Q1 2024 | Feb 14, 2024 | $3.25 | $-1.50 | -146.2% | ✗ MISS |
Q4 2023 | Dec 29, 2023 | $-0.44 | $-1.75 | -300.0% | ✗ MISS |
Q3 2023 | Aug 14, 2023 | $-1.50 | $-1.50 | 0.0% | = MET |
Q2 2023 | May 12, 2023 | $-1.00 | $-1.75 | -75.0% | ✗ MISS |
Q1 2023 | Feb 10, 2023 | — | $-1.00 | — | — |
Q4 2022 | Dec 22, 2022 | $-1.00 | $-1.25 | -25.0% | ✗ MISS |
Q3 2022 | Aug 11, 2022 | $-1.25 | $-1.50 | -20.0% | ✗ MISS |
Q2 2022 | May 12, 2022 | $-2.00 | $-1.25 | +37.5% | ✓ BEAT |
Q1 2022 | Feb 10, 2022 | $-1.50 | $-1.50 | 0.0% | = MET |
Q4 2021 | Dec 15, 2021 | $-0.75 | $-0.75 | 0.0% | = MET |
Q3 2021 | Aug 12, 2021 | $-1.25 | $-1.25 | 0.0% | = MET |
Q2 2021 | May 13, 2021 | $-2.00 | $-1.00 | +50.0% | ✓ BEAT |
Latest News
D. Boral Capital Maintains Buy on Citius Pharmaceuticals, Maintains $6 Price Target
📈 PositiveBenzinga•Dec 4, 2025, 06:00 PM
Citius Pharma Subsidiary Announces Commercial Launch Of LYMPHIR, IL-2 Receptor-Directed Fusion Protein For r/r Stage I–III Cutaneous T-Cell Lymphoma Treatment
📈 PositiveBenzinga•Dec 1, 2025, 05:06 PM•Also:
Citius Pharmaceuticals shares are trading lower after the company announced a $6 million registered direct offering.
📉 NegativeBenzinga•Oct 21, 2025, 12:10 PM
Citius Pharmaceuticals Announces $6M Citius Pharmaceuticals Announces a Registered Direct Offering; 3,973,510 Shares At $1.51/Share
➖ NeutralBenzinga•Oct 21, 2025, 12:04 PM
Citius Oncology and Citius Pharmaceuticals shares are trading higher after announcing the deployment of an AI platform to bolster commercial strategies ahead of the LYMPHIR launch.
📈 PositiveBenzinga•Aug 22, 2025, 01:03 PM•Also:
Citius Pharmaceuticals announces registered direct offering of $15.8 million
📉 NegativeSeeking Alpha•Jun 10, 2025, 11:40 AM
Frequently Asked Questions about CTXR
What is CTXR's current stock price?
Citius Pharmaceuticals, Inc. (CTXR) is currently trading at $1.07 per share. The stock has moved +4.39% today.
What is the analyst price target for CTXR?
No analyst price targets are currently available for this stock.
What sector is Citius Pharmaceuticals, Inc. in?
Citius Pharmaceuticals, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is CTXR's market cap?
Citius Pharmaceuticals, Inc. has a market capitalization of $0.01 billion, making it a small-cap company.
Does CTXR pay dividends?
No, Citius Pharmaceuticals, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorADTX
Aditxt, Inc.
$1.17
Mkt Cap: $0.0B
APLM
Apollomics, Inc.
$16.73
Mkt Cap: $0.0B
ATHA
Athira Pharma, Inc.
$6.97
Mkt Cap: $0.0B
CRIS
Curis, Inc.
$1.07
Mkt Cap: $0.0B
DARE
Daré Bioscience, Inc.
$2.09
Mkt Cap: $0.0B
FBLG
FibroBiologics, Inc. Common Stock
$0.26
Mkt Cap: $0.0B
ICU
SeaStar Medical Holding Corporation
$0.24
Mkt Cap: $0.0B
LNAI
Lunai Bioworks Inc.
$1.05
Mkt Cap: $0.0B
LPTX
Leap Therapeutics, Inc.
$1.09
Mkt Cap: $0.0B
MBRX
Moleculin Biotech, Inc.
$3.90
Mkt Cap: $0.0B
Explore stocks similar to CTXR for comparison